Lv0
0 积分 2026-04-10 加入
Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial
1个月前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study
1个月前
已完结
Efficacy and safety of SHR-1701 combined with chemoradiotherapy as neoadjuvant treatment for locally advanced rectal cancer
2个月前
已完结
Neoadjuvant chemoradiation with or without PD-1 blockade in locally advanced rectal cancer: a randomized phase 2 trial
2个月前
已完结
Total Neoadjuvant Therapy With PD-1 Blockade for High-Risk Proficient Mismatch Repair Rectal Cancer
2个月前
已完结
Intratumoral immunotherapy: using the tumor as the remedy
3个月前
已完结
Multiregional profiling reveals THBS1-SPP1 monocyte-macrophage axis drives immunosuppression and outcome in colorectal liver metastases
3个月前
已完结
Regulation of Immune Checkpoints: From Molecular Mechanisms to Clinical Therapies
3个月前
已完结
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial
3个月前
已完结
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer
3个月前
已完结
皖公网安备34019202002308
